Aveanna price target raised to $9.50 from $9 at Barclays
Barclays raised the firm's price target on Aveanna to $9.50 from $9 and keeps an Overweight rating on the shares. The firm adjusted targets among its U.S. healthcare facilities and managed care coverage ahead of Q2 earnings from the group.
Barclays raised the firm's price target on Aveanna to $9.50 from $9 and keeps an Overweight rating on the shares.
The firm adjusted targets among its U.S. healthcare facilities and managed care coverage ahead of Q2 earnings from the group.